NYBC Ventures
Corporate VCSeed–Series B · 8 people tracked
Investment thesis
NYBC Ventures is a corporate venture fund launched by New York Blood Center Enterprises with a $50M commitment to accelerate breakthroughs in blood and cellular therapies and supporting technologies. It leverages New York Blood Center's decades of expertise in blood products, transfusion services, and cell and gene therapy manufacturing. The fund targets early to mid stage innovations across hematology, transfusion medicine, cell therapy, and infectious disease, supporting therapeutics, devices, and other breakthrough solutions that address key challenges in these fields and ultimately improve patient lives.
Source: firm website, verified Aug 7, 2026.
Team · 8 people
from the firm's websiteWhat they invest in
from 6 of 13 portfolio companiesBiotech ×6Healthtech ×4Medical Devices ×3Advanced Manufacturing ×2Deep Tech ×2Robotics ×1
HQs:United States×5United Kingdom×1
Investments · 13 tracked
founders shown can be your intro pathAkadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US
Jeffrey S. Williams(Director)Brandon McNaughton(Executive Officer, Director)James Militello(Executive Officer)Kalyan Handique(Executive Officer, Director)Douglas Neal(Director)John Younger(Executive Officer, Director)
Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
Advanced ManufacturingBiotechRoboticsCambridge, GB
Functional Fluidics develops diagnostic tools to objectively monitor red blood cell health in patients with Sickle Cell Disease.
BiotechHealthtechMedical DevicesDetroit, US
John Cunningham(Chief Operating Officer)Patrick Hines(CEO & Founder)
Immusoft develops novel therapeutic treatments by programming B cells to produce therapeutic proteins for patients with rare and other diseases with significant unmet medical need.
BiotechSeattle, US
Matthew Scholz(Founder)Mark Ahn, Ph.D.(Director)Sean Ainsworth(Chief Executive Officer)
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Frequently asked questions
- What stage does NYBC Ventures invest at?
- NYBC Ventures invests at the Seed, Series A, Series B stages.
- What sectors does NYBC Ventures focus on?
- NYBC Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Does NYBC Ventures lead rounds?
- NYBC Ventures typically participates in rounds rather than leading them.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital is a venture and growth investment firm that backs technology companies, including a dedicated Resilience Tech practice focused on energy, industrial and infrastructure systems.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.